Cargando…

Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)

Detalles Bibliográficos
Autores principales:	Mahajan, Kunal, Gaur, Naresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Diabetes India. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245264/ https://www.ncbi.nlm.nih.gov/pubmed/32473902 http://dx.doi.org/10.1016/j.dsx.2020.05.029

Ejemplares similares

Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Letter in response to letter to the editor by Singh and Dhibar regarding the article “COVID-19: From bench to bedside” (Singh et al.)
por: Singh, Akriti, et al.
Publicado: (2020)

Reply to the letter of Singh and Singh in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis” (Kumar et al.)
por: Kumar, Ashish, et al.
Publicado: (2020)

Letter to editor in response to article “COVID-19: From bench to bedside” (Singh et al.)
por: Singh, Harpreet, et al.
Publicado: (2020)

Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
por: Mahajan, Kunal, et al.
Publicado: (2020)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Letter to editor in response to “COVID-19: From bench to bedside” by Singh A et al.
por: Singh, Harpreet, et al.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Not all thrombocytopenic bleeding is the same: Response to Singh et al.
por: Singh, Suvir
Publicado: (2021)

Response to Singh and Singh
por: Calder, Philip C.
Publicado: (2022)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension
por: Kuzeytemiz, Mustafa, et al.
Publicado: (2022)

Retraction for Singh et al. Performance evaluation of DNA Motif discovery programs
Publicado: (2015)

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
por: South, Andrew M., et al.
Publicado: (2020)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

A Letter to the Editor on the Article by Farnam et al
por: Rutte, Anne, et al.
Publicado: (2015)

Letter to the editor regarding the article of Chen et al.
por: Islamoglu, Mehmet Sami, et al.
Publicado: (2022)

Renin–Angiotensin System Implications to COVID-19 Comorbidities
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension
por: Wei, Jie, et al.
Publicado: (2019)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2
por: Lévy, Bernard I., et al.
Publicado: (2020)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Impact of renin-angiotensin system inhibitors and beta-blockers on dental implant stability
por: Saravi, Babak, et al.
Publicado: (2021)

Impact of Renin‐Angiotensin System Blockers on Mortality in Veterans Undergoing Cardiac Surgery
por: Antoniak, Derrick T., et al.
Publicado: (2021)

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023)

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
por: Konoshita, Tadashi, et al.
Publicado: (2009)

Erratum to “Letter to editor in response to “COVID-19: From bench to bedside” by Singh A et al.” [Diabetes & Metab Syndrome: Clin Res Rev 14 (5) (2020) 815–816 of duplicate article]
por: Singh, Harpreet, et al.
Publicado: (2020)

Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
por: Gressens, Simon B., et al.
Publicado: (2021)

Nadia Singh
por: Marwaha, Seema
Publicado: (2021)

Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.)
por: Ekiz, Timur, et al.
Publicado: (2020)

Letter to the Editor From Singh et al: “Female Adult Acne and Androgen Excess: A Report from the Multidisciplinary Androgen Excess and PCOS Committee”
por: Singh, Pritika, et al.
Publicado: (2022)

Angiotensin II Receptor Blocker Attenuates Intrarenal Renin-Angiotensin-System and Podocyte Injury in Rats with Myocardial Infarction
por: Wen, Zhu-zhi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4bckromsk1poj3nah0j9655kei